The invention claimed is:

1. A liquid composition for oral administration comprising saponin and chokeberry fruit extract, characterized in that saponin is β-escin, which is present in the composition at a concentration between 20 to 80 mg/l and the chokeberry fruits extract is present in the amount sufficient to mask the taste of β-escin for use in the treatment and/or prevention of metabolic conditions related to the increased acetaldehyde toxicity.

2. The composition of claim 1, wherein the concentration of β-escin is between 50 mg/l to 75 mg/l.

3. The composition of claim 2, wherein the concentration of β-escin is 62.5 mg/l.

4. The composition of claim 1, wherein the chokeberry fruit extract is present in the composition at the concentration between 50 to 200 g/l.

5. The composition of claim 4, wherein chokeberry fruit extract is present in the composition at the concentration between 100 g/l to 150 g/l.

6. The composition of claim 5, wherein chokeberry fruit extract is present in the composition at the concentration between 115 g/l to 135 g/l.

7. The composition of claim 6, wherein chokeberry fruit extract is present in the composition at the concentration of 125 g/l.

8. The composition of claim 1, wherein chokeberry fruit extract is chokeberry fruit juice concentrate.

9. The composition of claim 8, wherein β-escin is present at a concentration of 62.5 mg/l and the chokeberry fruit juice concentrate is present at the concentration of 125 g/l.

10. The composition of claim 1, further comprising a solvent.

11. The composition of claim 10, wherein the solvent is water or ethanol.

12. The composition of claim 1, further comprising one or more additives selected from the group consisting of flavourings, preservatives, vitamins, sweeteners, anti-

foaming agents, antioxidants, CO_2 and minerals.

13. The composition of claim 1, wherein the total volume of the composition is between 50 ml to 500 ml.

14. The composition of claim 13, wherein the total volume of the composition is between 100 ml to 330 ml.

15. The composition of claim 14, wherein the total volume of the composition is between 220 to 300 ml.

16. The composition of claim 15, wherein the total volume of the composition is 275 ml.

17. The composition of claim 1, wherein the metabolic condition is selected from the group consisting of veisalgia, alcohol poisoning esophageal cancer, oropharyngolaryngeal cancer and a condition resulting from insufficient aldehyde dehydrogenase (ALDH) enzyme activity.

18. The composition of claim 17, wherein the metabolic condition is a condition resulting from insufficient aldehyde dehydrogenase (ALDH) enzyme activity and a subject has a genetic mutation ALDH2*2.